Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 30.00
(+123.05%)
Based on the Mineralys Therapeutics, Inc. Common Stock stock forecast from 1 analysts, the average analyst target price for Mineralys Therapeutics, Inc. Common Stock is USD 30.00 over the next 12 months. Mineralys Therapeutics, Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Mineralys Therapeutics, Inc. Common Stock is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Mineralys Therapeutics, Inc. Common Stock’s stock price was USD 13.78. Mineralys Therapeutics, Inc. Common Stock’s stock price has changed by +0.80% over the past week, +13.79% over the past month and +77.81% over the last year.
No recent analyst target price found for Mineralys Therapeutics, Inc. Common Stock
No recent average analyst rating found for Mineralys Therapeutics, Inc. Common Stock
Company Overview Mineralys Therapeutics, Inc. Common Stock
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for Mineralys Therapeutics, Inc. Common Stock (MLYS)
Loading...
Unadjusted Closing Price for Mineralys Therapeutics, Inc. Common Stock (MLYS)
Loading...
Share Trading Volume for Mineralys Therapeutics, Inc. Common Stock Shares
Loading...
Compare Performance of Mineralys Therapeutics, Inc. Common Stock Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for MLYS
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Mineralys Therapeutics, Inc. Common Stock (Sector: Biotechnology )
Frequently Asked Questions About Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock
Based on ratings from 1 analysts Mineralys Therapeutics, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on MLYS's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for MLYS is USD 30.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 30.
Unfortunately we do not have enough data on MLYS's stock to indicate if its overvalued.
The last closing price of MLYS's stock was USD 13.78.
Unfortunately we do not currently have any market capitalization data for MLYS's stock.
Based on targets from 1 analysts, the average taret price for MLYS is projected at USD 30.00 over the next 12 months.
This means that MLYS's stock price may go up by +123.05% over the next 12 months.
We can't find any ETFs which contains Mineralys Therapeutics, Inc. Common Stock's stock.
Sorry, we do not have any data on the number of employees for Mineralys Therapeutics, Inc. Common Stock.
Sorry we do not have any infomation available on Mineralys Therapeutics, Inc. Common Stock's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock
Based on ratings from 1 analysts Mineralys Therapeutics, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on MLYS's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for MLYS is USD 30.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 30.
Unfortunately we do not have enough data on MLYS's stock to indicate if its overvalued.
The last closing price of MLYS's stock was USD 13.78.
Unfortunately we do not currently have any market capitalization data for MLYS's stock.
Based on targets from 1 analysts, the average taret price for MLYS is projected at USD 30.00 over the next 12 months.
This means that MLYS's stock price may go up by +123.05% over the next 12 months.
We can't find any ETFs which contains Mineralys Therapeutics, Inc. Common Stock's stock.
Sorry, we do not have any data on the number of employees for Mineralys Therapeutics, Inc. Common Stock.
Sorry we do not have any infomation available on Mineralys Therapeutics, Inc. Common Stock's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MLYS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
